Maxime Frelaut
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Maxime Frelaut has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- Capucine Baldini
Département d’Innovation Thérapeutique et d’Essais Précoces (DITEP), Gustave Roussy Cancer Campus, Université Paris-Saclay, 94805 Villejuif, France
5 shared publications - Florence Canoui-Poitrine
Service de Santé Publique, GHU AP-HP Hôpitaux Universitaires Henri-Mondor, Créteil; UMR U955 - UPEC/Inserm U955, Faculté de Médecine de Créteil, Créteil, France; Département Masters, Faculté de Santé - UPEC, Créteil, France
3 shared publications - Julieta Rodriguez
Drug Development Department, Gustave Roussy Cancer Campus, Villejuif, France
3 shared publications - Marco Tagliamento
University of Genova 12 Department of Internal Medicine and Medical Specialties Genova, Italy
3 shared publications A. Larive
Gustave Roussy, Department of Biostatistics and Epidemiology, Villejuif, France
2 shared publications- Anna Rachelle Mislang
Department of Medical Oncology, Flinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University, Bedford Park, SA 5042, Australia
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
The ESMO/SIOG Cancer in the Elderly Working Group pragmatic strategies for clinical trial designs and endpoints in older adults with cancer
- 3 January 2025
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 55 (1)
Reliability of the cumulative illness rating scale for geriatrics for assessing multimorbidity in older patients with cancer: results from the ELCAPA cohort
Comorbidities are common in older patients with cancer. The Cumulative Illness Rating Scale for Geriatrics (CIRS-G, developed in 1992) provides a comprehensive assessment of comorbidities and is independently associated with the mortality rate, the hospital admission rate and functional limitations. Although the literature data indicate that the CIRS-G’s reliability is good to very good, most of the studies were small and did not include cancer patients. Here, we evaluated the CIRS-G’s reliability in a large, prospective cohort of cancer patients aged 70 or over. A stratified, random sample of 150 patients was used to assess inter-rater reliability, and a random sample of 30 patients was evaluated by two investigators to assess intra-rater reliability. For inter-rater reliability, the observed intraclass correlation coefficient (ICC) [95% confidence interval] of 0.53 [0.12–0.74] was substantially lower than the literature values. For intra-rater reliability, the ICC was 0.66 [0.40–0.82] for investigator 1 and 0.77 [0.54–0.89) for investigator 2. These findings suggest that applying the CIRS-G consistently across raters and centres may be challenging in real-world oncology settings for older patients with cancer. Revising the scoring guidelines could help improve its reliability.
- 3 January 2025
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 55 (1)
Reliability of the cumulative illness rating scale for geriatrics for assessing multimorbidity in older patients with cancer: results from the ELCAPA cohort
Comorbidities are common in older patients with cancer. The Cumulative Illness Rating Scale for Geriatrics (CIRS-G, developed in 1992) provides a comprehensive assessment of comorbidities and is independently associated with the mortality rate, the hospital admission rate and functional limitations. Although the literature data indicate that the CIRS-G’s reliability is good to very good, most of the studies were small and did not include cancer patients. Here, we evaluated the CIRS-G’s reliability in a large, prospective cohort of cancer patients aged 70 or over. A stratified, random sample of 150 patients was used to assess inter-rater reliability, and a random sample of 30 patients was evaluated by two investigators to assess intra-rater reliability. For inter-rater reliability, the observed intraclass correlation coefficient (ICC) [95% confidence interval] of 0.53 [0.12–0.74] was substantially lower than the literature values. For intra-rater reliability, the ICC was 0.66 [0.40–0.82] for investigator 1 and 0.77 [0.54–0.89) for investigator 2. These findings suggest that applying the CIRS-G consistently across raters and centres may be challenging in real-world oncology settings for older patients with cancer. Revising the scoring guidelines could help improve its reliability.
- Top Cited PapersOpen Access
Adequate assessment yields appropriate care—the role of geriatric assessment and management in older adults with cancer: a position paper from the ESMO/SIOG Cancer in the Elderly Working Group
- Open Access
- 21 March 2024
- Published by Elsevier in The Journal of nutrition, health and aging
- Vol. 28 (5) , 100215
Prognostic impact of neurocognitive disorders in older patients with cancer: the ELCAPA prospective cohort study
- 21 March 2024
- Published by Elsevier in The Journal of nutrition, health and aging
- Vol. 28 (5) , 100215
Open AccessPrognostic impact of neurocognitive disorders in older patients with cancer: the ELCAPA prospective cohort study
- 5 November 2023
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 14 (8) , S19
Clonal Hematopoiesis of indeterminate potential in patients with advanced NSCLC treated with ICB
- 5 November 2023
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 14 (8) , S19
Clonal Hematopoiesis of indeterminate potential in patients with advanced NSCLC treated with ICB
- 20 October 2023
- Published by Elsevier in Annals of Oncology
- Vol. 34, S1176-S1177
2300P Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study
- 20 October 2023
- Published by Elsevier in Annals of Oncology
- Vol. 34, S1176-S1177
2300P Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study
- Open Access
Bridging the gap: addressing disparities of access to oncology clinical trials in the geriatric population
- 1 June 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (16_suppl) , 12062
Frailty IO: Frailty parameters and incidence of immune related adverse events in older patients treated with immune checkpoint blockers (ICB).
- 1 June 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (16_suppl) , 12062
Frailty IO: Frailty parameters and incidence of immune related adverse events in older patients treated with immune checkpoint blockers (ICB).
- Open Access
- 7 April 2023
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 28 (6) , e341-e349
External Validity of Two Scores for Predicting the Risk of Chemotherapy Toxicity Among Older Patients With Solid Tumors: Results From the ELCAPA Prospective Cohort
Severe chemotherapy-related toxicities are frequent among older patients. The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) and the Cancer and Aging Research Group Study (CARG) score were both developed to predict these events. The objective of this study was to evaluate the scores’ predictive performance in a prospective cohort, which included patients aged 70 years and older referred for a geriatric assessment prior to chemotherapy for a solid tumor. The main endpoints were grades 3/4/5 toxicities for the CARG score and grades 4/5 hematologic toxicities and grades 3/4/5 non-hematologic toxicities for the CRASH score. A total of 248 patients were included, of which 150 (61%) and 126 (51%) experienced at least one severe adverse event as defined respectively in CARG and CRASH studies. The incidence of adverse events was not significantly greater in the intermediate and high-risk CARG groups than in the low-risk group (odds ratio (OR) [95% CI] = 0.3 [0.1-1.4] (P = .1) and 0.4 [0.1-1.7], respectively). The area under curve (AUC) was 0.55. Similarly, the incidence of severe toxicities was no greater in the intermediate-low, intermediate-high, and high-risk CRASH groups than in the low-risk CRASH group (OR [95%CI] = 1 [0.3-3.6], 1 [0.3-3.4], and 1.5 [0.3-8.1], respectively). The AUC was 0.52. The type of cancer, performance status, comorbidities, body mass index, and MAX2 index were independently associated with grades 3/4/5 toxicities. In an external cohort of older patients referred for a pretherapeutic GA, the CARG and CRASH scores were poor predictors of the risk of chemotherapy severe toxicities.
- 7 April 2023
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 28 (6) , e341-e349
Open AccessExternal Validity of Two Scores for Predicting the Risk of Chemotherapy Toxicity Among Older Patients With Solid Tumors: Results From the ELCAPA Prospective Cohort
Severe chemotherapy-related toxicities are frequent among older patients. The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) and the Cancer and Aging Research Group Study (CARG) score were both developed to predict these events. The objective of this study was to evaluate the scores’ predictive performance in a prospective cohort, which included patients aged 70 years and older referred for a geriatric assessment prior to chemotherapy for a solid tumor. The main endpoints were grades 3/4/5 toxicities for the CARG score and grades 4/5 hematologic toxicities and grades 3/4/5 non-hematologic toxicities for the CRASH score. A total of 248 patients were included, of which 150 (61%) and 126 (51%) experienced at least one severe adverse event as defined respectively in CARG and CRASH studies. The incidence of adverse events was not significantly greater in the intermediate and high-risk CARG groups than in the low-risk group (odds ratio (OR) [95% CI] = 0.3 [0.1-1.4] (P = .1) and 0.4 [0.1-1.7], respectively). The area under curve (AUC) was 0.55. Similarly, the incidence of severe toxicities was no greater in the intermediate-low, intermediate-high, and high-risk CRASH groups than in the low-risk CRASH group (OR [95%CI] = 1 [0.3-3.6], 1 [0.3-3.4], and 1.5 [0.3-8.1], respectively). The AUC was 0.52. The type of cancer, performance status, comorbidities, body mass index, and MAX2 index were independently associated with grades 3/4/5 toxicities. In an external cohort of older patients referred for a pretherapeutic GA, the CARG and CRASH scores were poor predictors of the risk of chemotherapy severe toxicities.